The Experts below are selected from a list of 303 Experts worldwide ranked by ideXlab platform
Mohammad Mehdi Sadoughi - One of the best experts on this subject based on the ideXlab platform.
-
randomized trial of intravitreal clindamycin and dexamethasone versus Pyrimethamine Sulfadiazine and prednisolone in treatment of ocular toxoplasmosis
Ophthalmology, 2011Co-Authors: Masoud Soheilian, Mohammad Mehdi Sadoughi, Mohammad H Dehghan, Alireza Ramezani, Ahmad Azimzadeh, Reza Shahghadami, Mehdi Yaseri, Gholam A PeymanAbstract:Purpose To compare the efficacy of intravitreal injection of clindamycin and dexamethasone with classic treatment for ocular toxoplasmosis. Design Prospective, randomized single-masked clinical trial. Participants A total of 68 patients with active ocular toxoplasmosis were assigned randomly to 2 treatment groups: 34 in the intravitreal clindamycin plus dexamethasone (IVCD) group and 34 in the classic treatment (CT) group. Intervention The IVCD group received 1 to 3 injection(s) of 1 mg intravitreal clindamycin and 400 μg dexamethasone, and the CT group received 6 weeks of treatment with Pyrimethamine and Sulfadiazine plus prednisolone. Antitoxoplasmosis antibodies (immunoglobulin [Ig] M and IgG) were measured using an enzyme-linked immunosorbent assay. Main Outcome Measures Changes in retinochoroidal lesion size, measured by a computer program written in the MATLAB environment, 6 weeks after initiation of treatment. Visual acuity (VA) changes, vitreous inflammatory response, adverse drug reactions, and rate of recurrence were secondary outcome measures. Results The mean number of injections in the IVCD group was 1.6. The lesion size reduction was statistically significant after treatment in both IVCD and CT groups ( P P = 0.009, respectively). However, the difference in mean percentage of reduction at 6 weeks was not significant: 57.0±27.8% in the IVCD group versus 58.4±29.3% in the CT group ( P = 0.569). In relation to the baseline, VA increased by 0.44±0.24 and 0.29±0.19 logarithm of the minimum angle of resolution units in the IVCD and CT groups, respectively ( P P = 0.002); this indicated that IgM-positive cases responded better to CT and IgM-negative cases responded better to IVCD treatment. Vitreous inflammation reduction was insignificant between the groups. Within 2 years, 4 eyes (2 in each group) had 1 episode of recurrence. Adverse drug reactions occurred in 2 patients in the CT group. No major injection-related complication was encountered in the IVCD group. Conclusions Intravitreal injection of clindamycin and dexamethasone may be an acceptable alternative to the classic treatment in ocular toxoplasmosis. It may offer the patient more convenience, a safer systemic side effect profile, greater availability, and fewer follow-up visits and hematologic evaluations. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.
-
Short-term Results of Two Treatment Regimens in Ocular Toxoplasmosis: Trimethoprim/Sulfamethoxazole versus Pyrimethamine and Sulfadiazine
Journal of ophthalmic and vision research, 2006Co-Authors: Mohammad Mehdi Sadoughi, Mohammad H Dehghan, Hassan Behboudi, Arash Anisian, Soheylian Masoud, Yazdani ShahinAbstract:Purpose : To compare the efficacy of classic treatment for ocular toxoplasmosis (Pyrimethamine, Sulfadiazine and predinsolone) with a regimen consisting of trimethoprim/sulfamethoxazole (TMP/SMX) [co-trimoxazole] plus predinsolone. Methods : In a prospective randomized single-blind clinical trial, 59 patients with active ocular toxoplasmosis were randomly assigned to two treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine and 30 patients received TMP/SMX. Treatment consisted of six weeks treatment with antibiotics plus steroids. Anti-toxoplasmosis antibodies (IgM and IgG) were measured using ELISA. Outcome measures included changes in retinochoroidal lesion size after six weeks of treatment, visual acuity before and after intervention, adverse drug reactions during follow up and rate of recurrence. Results : Active toxoplasmosis retinochoroiditis resolved in all patients over six weeks of treatment with no significant difference in mean reduction in retinochoroidal lesion size between the two treatment groups (61% reduction in the classic treatment group and 59% in the TMP/SMX group, P=0.75). Similarly no significant difference was found in visual acuity after treatment between the two groups [mean visual acuity after treatment was 0.12 LogMAR (20/25) in classic treatment group and 0.09LogMAR (20/25) in TMP/SMX group, P = 0.56]. Adverse events were similar in both groups with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 14 months of follow up was 6.7% with no significant difference between the treatment groups (P = 0.48). Conclusion : Drug efficacy in terms of reduction in retinal lesion size and improvement in visual acuity was similar between a regimen of TMP/SMX and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with TMP/SMX appears to be an acceptable alternative for the treatment of ocular toxoplasmosis.
-
short term results of two treatment regimens in ocular toxoplasmosis trimethoprim sulfamethoxazole versus Pyrimethamine and Sulfadiazine
Journal of ophthalmic and vision research, 2006Co-Authors: Mohammad Mehdi Sadoughi, Mohammad H Dehghan, Hassan Behboudi, Arash Anisian, Soheylian Masoud, Yazdani ShahinAbstract:Purpose : To compare the efficacy of classic treatment for ocular toxoplasmosis (Pyrimethamine, Sulfadiazine and predinsolone) with a regimen consisting of trimethoprim/sulfamethoxazole (TMP/SMX) [co-trimoxazole] plus predinsolone. Methods : In a prospective randomized single-blind clinical trial, 59 patients with active ocular toxoplasmosis were randomly assigned to two treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine and 30 patients received TMP/SMX. Treatment consisted of six weeks treatment with antibiotics plus steroids. Anti-toxoplasmosis antibodies (IgM and IgG) were measured using ELISA. Outcome measures included changes in retinochoroidal lesion size after six weeks of treatment, visual acuity before and after intervention, adverse drug reactions during follow up and rate of recurrence. Results : Active toxoplasmosis retinochoroiditis resolved in all patients over six weeks of treatment with no significant difference in mean reduction in retinochoroidal lesion size between the two treatment groups (61% reduction in the classic treatment group and 59% in the TMP/SMX group, P=0.75). Similarly no significant difference was found in visual acuity after treatment between the two groups [mean visual acuity after treatment was 0.12 LogMAR (20/25) in classic treatment group and 0.09LogMAR (20/25) in TMP/SMX group, P = 0.56]. Adverse events were similar in both groups with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 14 months of follow up was 6.7% with no significant difference between the treatment groups (P = 0.48). Conclusion : Drug efficacy in terms of reduction in retinal lesion size and improvement in visual acuity was similar between a regimen of TMP/SMX and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with TMP/SMX appears to be an acceptable alternative for the treatment of ocular toxoplasmosis.
-
prospective randomized trial of trimethoprim sulfamethoxazole versus Pyrimethamine and Sulfadiazine in the treatment of ocular toxoplasmosis
Ophthalmology, 2005Co-Authors: Masoud Soheilian, Mohammad Mehdi Sadoughi, Mehdi Ghajarnia, Mohammad H Dehghan, Shahin Yazdani, Hassan Behboudi, Arash Anisian, Gholam A PeymanAbstract:Objective To compare the efficacy of the classic treatment of ocular toxoplasmosis (Pyrimethamine, Sulfadiazine, and prednisolone) with a regimen consisting of trimethoprim/sulfamethoxazole (co-trimoxazole) plus prednisolone. Design Prospective randomized single-blind clinical trial. Participants Fifty-nine patients with active ocular toxoplasmosis were randomly assigned to 2 treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine, and 30 patients received trimethoprim/sulfamethoxazole. Intervention Treatment consisted of 6 weeks' treatment with antibiotics plus steroids. Antitoxoplasmosis antibodies (immunoglobulin M [IgM] and IgG) were measured using an enzyme-linked immunosorbent assay. Main Outcome Measures Changes in retinochoroidal lesion size after 6 weeks' treatment, visual acuity (VA) before and after intervention, adverse drug reactions during follow-up, and rate of recurrence. Results Active toxoplasmosis retinochoroiditis resolved in all patients over 6 weeks' treatment, with no significant difference in mean reduction of retinochoroidal lesion size between the 2 treatment groups (61% reduction in the classic treatment group and 59% in the trimethoprim/sulfamethoxazole group, P = 0.75). Similarly, no significant difference was found in VA after treatment between the 2 groups (mean VAs after treatment were 0.12 logarithm of the minimum angle of resolution [logMAR] [20/25] in the classic treatment group and 0.09 logMAR [20/25] in the trimethoprim/sulfamethoxazole group, P = 0.56). Adverse effects were similar in both groups, with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 24 months' follow-up was 10.16%, with no significant difference between the treatment groups ( P = 0.64). Conclusions Drug efficacies in terms of reduction in retinal lesion size and improvement in VA were similar in a regimen of trimethoprim/sulfamethoxazole and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with trimethoprim/sulfamethoxazole seems to be an acceptable alternative for the treatment of ocular toxoplasmosis.
-
Prospective randomized trial of trimethoprim/sulfamethoxazole versus Pyrimethamine and Sulfadiazine in the treatment of ocular toxoplasmosis.
Ophthalmology, 2005Co-Authors: Masoud Soheilian, Mohammad Mehdi Sadoughi, Mehdi Ghajarnia, Mohammad H Dehghan, Shahin Yazdani, Hassan Behboudi, Arash Anisian, Gholam A PeymanAbstract:Objective To compare the efficacy of the classic treatment of ocular toxoplasmosis (Pyrimethamine, Sulfadiazine, and prednisolone) with a regimen consisting of trimethoprim/sulfamethoxazole (co-trimoxazole) plus prednisolone. Design Prospective randomized single-blind clinical trial. Participants Fifty-nine patients with active ocular toxoplasmosis were randomly assigned to 2 treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine, and 30 patients received trimethoprim/sulfamethoxazole. Intervention Treatment consisted of 6 weeks' treatment with antibiotics plus steroids. Antitoxoplasmosis antibodies (immunoglobulin M [IgM] and IgG) were measured using an enzyme-linked immunosorbent assay. Main Outcome Measures Changes in retinochoroidal lesion size after 6 weeks' treatment, visual acuity (VA) before and after intervention, adverse drug reactions during follow-up, and rate of recurrence. Results Active toxoplasmosis retinochoroiditis resolved in all patients over 6 weeks' treatment, with no significant difference in mean reduction of retinochoroidal lesion size between the 2 treatment groups (61% reduction in the classic treatment group and 59% in the trimethoprim/sulfamethoxazole group, P = 0.75). Similarly, no significant difference was found in VA after treatment between the 2 groups (mean VAs after treatment were 0.12 logarithm of the minimum angle of resolution [logMAR] [20/25] in the classic treatment group and 0.09 logMAR [20/25] in the trimethoprim/sulfamethoxazole group, P = 0.56). Adverse effects were similar in both groups, with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 24 months' follow-up was 10.16%, with no significant difference between the treatment groups ( P = 0.64). Conclusions Drug efficacies in terms of reduction in retinal lesion size and improvement in VA were similar in a regimen of trimethoprim/sulfamethoxazole and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with trimethoprim/sulfamethoxazole seems to be an acceptable alternative for the treatment of ocular toxoplasmosis.
Gholam A Peyman - One of the best experts on this subject based on the ideXlab platform.
-
randomized trial of intravitreal clindamycin and dexamethasone versus Pyrimethamine Sulfadiazine and prednisolone in treatment of ocular toxoplasmosis
Ophthalmology, 2011Co-Authors: Masoud Soheilian, Mohammad Mehdi Sadoughi, Mohammad H Dehghan, Alireza Ramezani, Ahmad Azimzadeh, Reza Shahghadami, Mehdi Yaseri, Gholam A PeymanAbstract:Purpose To compare the efficacy of intravitreal injection of clindamycin and dexamethasone with classic treatment for ocular toxoplasmosis. Design Prospective, randomized single-masked clinical trial. Participants A total of 68 patients with active ocular toxoplasmosis were assigned randomly to 2 treatment groups: 34 in the intravitreal clindamycin plus dexamethasone (IVCD) group and 34 in the classic treatment (CT) group. Intervention The IVCD group received 1 to 3 injection(s) of 1 mg intravitreal clindamycin and 400 μg dexamethasone, and the CT group received 6 weeks of treatment with Pyrimethamine and Sulfadiazine plus prednisolone. Antitoxoplasmosis antibodies (immunoglobulin [Ig] M and IgG) were measured using an enzyme-linked immunosorbent assay. Main Outcome Measures Changes in retinochoroidal lesion size, measured by a computer program written in the MATLAB environment, 6 weeks after initiation of treatment. Visual acuity (VA) changes, vitreous inflammatory response, adverse drug reactions, and rate of recurrence were secondary outcome measures. Results The mean number of injections in the IVCD group was 1.6. The lesion size reduction was statistically significant after treatment in both IVCD and CT groups ( P P = 0.009, respectively). However, the difference in mean percentage of reduction at 6 weeks was not significant: 57.0±27.8% in the IVCD group versus 58.4±29.3% in the CT group ( P = 0.569). In relation to the baseline, VA increased by 0.44±0.24 and 0.29±0.19 logarithm of the minimum angle of resolution units in the IVCD and CT groups, respectively ( P P = 0.002); this indicated that IgM-positive cases responded better to CT and IgM-negative cases responded better to IVCD treatment. Vitreous inflammation reduction was insignificant between the groups. Within 2 years, 4 eyes (2 in each group) had 1 episode of recurrence. Adverse drug reactions occurred in 2 patients in the CT group. No major injection-related complication was encountered in the IVCD group. Conclusions Intravitreal injection of clindamycin and dexamethasone may be an acceptable alternative to the classic treatment in ocular toxoplasmosis. It may offer the patient more convenience, a safer systemic side effect profile, greater availability, and fewer follow-up visits and hematologic evaluations. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.
-
prospective randomized trial of trimethoprim sulfamethoxazole versus Pyrimethamine and Sulfadiazine in the treatment of ocular toxoplasmosis
Ophthalmology, 2005Co-Authors: Masoud Soheilian, Mohammad Mehdi Sadoughi, Mehdi Ghajarnia, Mohammad H Dehghan, Shahin Yazdani, Hassan Behboudi, Arash Anisian, Gholam A PeymanAbstract:Objective To compare the efficacy of the classic treatment of ocular toxoplasmosis (Pyrimethamine, Sulfadiazine, and prednisolone) with a regimen consisting of trimethoprim/sulfamethoxazole (co-trimoxazole) plus prednisolone. Design Prospective randomized single-blind clinical trial. Participants Fifty-nine patients with active ocular toxoplasmosis were randomly assigned to 2 treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine, and 30 patients received trimethoprim/sulfamethoxazole. Intervention Treatment consisted of 6 weeks' treatment with antibiotics plus steroids. Antitoxoplasmosis antibodies (immunoglobulin M [IgM] and IgG) were measured using an enzyme-linked immunosorbent assay. Main Outcome Measures Changes in retinochoroidal lesion size after 6 weeks' treatment, visual acuity (VA) before and after intervention, adverse drug reactions during follow-up, and rate of recurrence. Results Active toxoplasmosis retinochoroiditis resolved in all patients over 6 weeks' treatment, with no significant difference in mean reduction of retinochoroidal lesion size between the 2 treatment groups (61% reduction in the classic treatment group and 59% in the trimethoprim/sulfamethoxazole group, P = 0.75). Similarly, no significant difference was found in VA after treatment between the 2 groups (mean VAs after treatment were 0.12 logarithm of the minimum angle of resolution [logMAR] [20/25] in the classic treatment group and 0.09 logMAR [20/25] in the trimethoprim/sulfamethoxazole group, P = 0.56). Adverse effects were similar in both groups, with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 24 months' follow-up was 10.16%, with no significant difference between the treatment groups ( P = 0.64). Conclusions Drug efficacies in terms of reduction in retinal lesion size and improvement in VA were similar in a regimen of trimethoprim/sulfamethoxazole and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with trimethoprim/sulfamethoxazole seems to be an acceptable alternative for the treatment of ocular toxoplasmosis.
-
Prospective randomized trial of trimethoprim/sulfamethoxazole versus Pyrimethamine and Sulfadiazine in the treatment of ocular toxoplasmosis.
Ophthalmology, 2005Co-Authors: Masoud Soheilian, Mohammad Mehdi Sadoughi, Mehdi Ghajarnia, Mohammad H Dehghan, Shahin Yazdani, Hassan Behboudi, Arash Anisian, Gholam A PeymanAbstract:Objective To compare the efficacy of the classic treatment of ocular toxoplasmosis (Pyrimethamine, Sulfadiazine, and prednisolone) with a regimen consisting of trimethoprim/sulfamethoxazole (co-trimoxazole) plus prednisolone. Design Prospective randomized single-blind clinical trial. Participants Fifty-nine patients with active ocular toxoplasmosis were randomly assigned to 2 treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine, and 30 patients received trimethoprim/sulfamethoxazole. Intervention Treatment consisted of 6 weeks' treatment with antibiotics plus steroids. Antitoxoplasmosis antibodies (immunoglobulin M [IgM] and IgG) were measured using an enzyme-linked immunosorbent assay. Main Outcome Measures Changes in retinochoroidal lesion size after 6 weeks' treatment, visual acuity (VA) before and after intervention, adverse drug reactions during follow-up, and rate of recurrence. Results Active toxoplasmosis retinochoroiditis resolved in all patients over 6 weeks' treatment, with no significant difference in mean reduction of retinochoroidal lesion size between the 2 treatment groups (61% reduction in the classic treatment group and 59% in the trimethoprim/sulfamethoxazole group, P = 0.75). Similarly, no significant difference was found in VA after treatment between the 2 groups (mean VAs after treatment were 0.12 logarithm of the minimum angle of resolution [logMAR] [20/25] in the classic treatment group and 0.09 logMAR [20/25] in the trimethoprim/sulfamethoxazole group, P = 0.56). Adverse effects were similar in both groups, with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 24 months' follow-up was 10.16%, with no significant difference between the treatment groups ( P = 0.64). Conclusions Drug efficacies in terms of reduction in retinal lesion size and improvement in VA were similar in a regimen of trimethoprim/sulfamethoxazole and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with trimethoprim/sulfamethoxazole seems to be an acceptable alternative for the treatment of ocular toxoplasmosis.
Mohammad H Dehghan - One of the best experts on this subject based on the ideXlab platform.
-
randomized trial of intravitreal clindamycin and dexamethasone versus Pyrimethamine Sulfadiazine and prednisolone in treatment of ocular toxoplasmosis
Ophthalmology, 2011Co-Authors: Masoud Soheilian, Mohammad Mehdi Sadoughi, Mohammad H Dehghan, Alireza Ramezani, Ahmad Azimzadeh, Reza Shahghadami, Mehdi Yaseri, Gholam A PeymanAbstract:Purpose To compare the efficacy of intravitreal injection of clindamycin and dexamethasone with classic treatment for ocular toxoplasmosis. Design Prospective, randomized single-masked clinical trial. Participants A total of 68 patients with active ocular toxoplasmosis were assigned randomly to 2 treatment groups: 34 in the intravitreal clindamycin plus dexamethasone (IVCD) group and 34 in the classic treatment (CT) group. Intervention The IVCD group received 1 to 3 injection(s) of 1 mg intravitreal clindamycin and 400 μg dexamethasone, and the CT group received 6 weeks of treatment with Pyrimethamine and Sulfadiazine plus prednisolone. Antitoxoplasmosis antibodies (immunoglobulin [Ig] M and IgG) were measured using an enzyme-linked immunosorbent assay. Main Outcome Measures Changes in retinochoroidal lesion size, measured by a computer program written in the MATLAB environment, 6 weeks after initiation of treatment. Visual acuity (VA) changes, vitreous inflammatory response, adverse drug reactions, and rate of recurrence were secondary outcome measures. Results The mean number of injections in the IVCD group was 1.6. The lesion size reduction was statistically significant after treatment in both IVCD and CT groups ( P P = 0.009, respectively). However, the difference in mean percentage of reduction at 6 weeks was not significant: 57.0±27.8% in the IVCD group versus 58.4±29.3% in the CT group ( P = 0.569). In relation to the baseline, VA increased by 0.44±0.24 and 0.29±0.19 logarithm of the minimum angle of resolution units in the IVCD and CT groups, respectively ( P P = 0.002); this indicated that IgM-positive cases responded better to CT and IgM-negative cases responded better to IVCD treatment. Vitreous inflammation reduction was insignificant between the groups. Within 2 years, 4 eyes (2 in each group) had 1 episode of recurrence. Adverse drug reactions occurred in 2 patients in the CT group. No major injection-related complication was encountered in the IVCD group. Conclusions Intravitreal injection of clindamycin and dexamethasone may be an acceptable alternative to the classic treatment in ocular toxoplasmosis. It may offer the patient more convenience, a safer systemic side effect profile, greater availability, and fewer follow-up visits and hematologic evaluations. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.
-
Short-term Results of Two Treatment Regimens in Ocular Toxoplasmosis: Trimethoprim/Sulfamethoxazole versus Pyrimethamine and Sulfadiazine
Journal of ophthalmic and vision research, 2006Co-Authors: Mohammad Mehdi Sadoughi, Mohammad H Dehghan, Hassan Behboudi, Arash Anisian, Soheylian Masoud, Yazdani ShahinAbstract:Purpose : To compare the efficacy of classic treatment for ocular toxoplasmosis (Pyrimethamine, Sulfadiazine and predinsolone) with a regimen consisting of trimethoprim/sulfamethoxazole (TMP/SMX) [co-trimoxazole] plus predinsolone. Methods : In a prospective randomized single-blind clinical trial, 59 patients with active ocular toxoplasmosis were randomly assigned to two treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine and 30 patients received TMP/SMX. Treatment consisted of six weeks treatment with antibiotics plus steroids. Anti-toxoplasmosis antibodies (IgM and IgG) were measured using ELISA. Outcome measures included changes in retinochoroidal lesion size after six weeks of treatment, visual acuity before and after intervention, adverse drug reactions during follow up and rate of recurrence. Results : Active toxoplasmosis retinochoroiditis resolved in all patients over six weeks of treatment with no significant difference in mean reduction in retinochoroidal lesion size between the two treatment groups (61% reduction in the classic treatment group and 59% in the TMP/SMX group, P=0.75). Similarly no significant difference was found in visual acuity after treatment between the two groups [mean visual acuity after treatment was 0.12 LogMAR (20/25) in classic treatment group and 0.09LogMAR (20/25) in TMP/SMX group, P = 0.56]. Adverse events were similar in both groups with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 14 months of follow up was 6.7% with no significant difference between the treatment groups (P = 0.48). Conclusion : Drug efficacy in terms of reduction in retinal lesion size and improvement in visual acuity was similar between a regimen of TMP/SMX and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with TMP/SMX appears to be an acceptable alternative for the treatment of ocular toxoplasmosis.
-
short term results of two treatment regimens in ocular toxoplasmosis trimethoprim sulfamethoxazole versus Pyrimethamine and Sulfadiazine
Journal of ophthalmic and vision research, 2006Co-Authors: Mohammad Mehdi Sadoughi, Mohammad H Dehghan, Hassan Behboudi, Arash Anisian, Soheylian Masoud, Yazdani ShahinAbstract:Purpose : To compare the efficacy of classic treatment for ocular toxoplasmosis (Pyrimethamine, Sulfadiazine and predinsolone) with a regimen consisting of trimethoprim/sulfamethoxazole (TMP/SMX) [co-trimoxazole] plus predinsolone. Methods : In a prospective randomized single-blind clinical trial, 59 patients with active ocular toxoplasmosis were randomly assigned to two treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine and 30 patients received TMP/SMX. Treatment consisted of six weeks treatment with antibiotics plus steroids. Anti-toxoplasmosis antibodies (IgM and IgG) were measured using ELISA. Outcome measures included changes in retinochoroidal lesion size after six weeks of treatment, visual acuity before and after intervention, adverse drug reactions during follow up and rate of recurrence. Results : Active toxoplasmosis retinochoroiditis resolved in all patients over six weeks of treatment with no significant difference in mean reduction in retinochoroidal lesion size between the two treatment groups (61% reduction in the classic treatment group and 59% in the TMP/SMX group, P=0.75). Similarly no significant difference was found in visual acuity after treatment between the two groups [mean visual acuity after treatment was 0.12 LogMAR (20/25) in classic treatment group and 0.09LogMAR (20/25) in TMP/SMX group, P = 0.56]. Adverse events were similar in both groups with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 14 months of follow up was 6.7% with no significant difference between the treatment groups (P = 0.48). Conclusion : Drug efficacy in terms of reduction in retinal lesion size and improvement in visual acuity was similar between a regimen of TMP/SMX and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with TMP/SMX appears to be an acceptable alternative for the treatment of ocular toxoplasmosis.
-
prospective randomized trial of trimethoprim sulfamethoxazole versus Pyrimethamine and Sulfadiazine in the treatment of ocular toxoplasmosis
Ophthalmology, 2005Co-Authors: Masoud Soheilian, Mohammad Mehdi Sadoughi, Mehdi Ghajarnia, Mohammad H Dehghan, Shahin Yazdani, Hassan Behboudi, Arash Anisian, Gholam A PeymanAbstract:Objective To compare the efficacy of the classic treatment of ocular toxoplasmosis (Pyrimethamine, Sulfadiazine, and prednisolone) with a regimen consisting of trimethoprim/sulfamethoxazole (co-trimoxazole) plus prednisolone. Design Prospective randomized single-blind clinical trial. Participants Fifty-nine patients with active ocular toxoplasmosis were randomly assigned to 2 treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine, and 30 patients received trimethoprim/sulfamethoxazole. Intervention Treatment consisted of 6 weeks' treatment with antibiotics plus steroids. Antitoxoplasmosis antibodies (immunoglobulin M [IgM] and IgG) were measured using an enzyme-linked immunosorbent assay. Main Outcome Measures Changes in retinochoroidal lesion size after 6 weeks' treatment, visual acuity (VA) before and after intervention, adverse drug reactions during follow-up, and rate of recurrence. Results Active toxoplasmosis retinochoroiditis resolved in all patients over 6 weeks' treatment, with no significant difference in mean reduction of retinochoroidal lesion size between the 2 treatment groups (61% reduction in the classic treatment group and 59% in the trimethoprim/sulfamethoxazole group, P = 0.75). Similarly, no significant difference was found in VA after treatment between the 2 groups (mean VAs after treatment were 0.12 logarithm of the minimum angle of resolution [logMAR] [20/25] in the classic treatment group and 0.09 logMAR [20/25] in the trimethoprim/sulfamethoxazole group, P = 0.56). Adverse effects were similar in both groups, with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 24 months' follow-up was 10.16%, with no significant difference between the treatment groups ( P = 0.64). Conclusions Drug efficacies in terms of reduction in retinal lesion size and improvement in VA were similar in a regimen of trimethoprim/sulfamethoxazole and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with trimethoprim/sulfamethoxazole seems to be an acceptable alternative for the treatment of ocular toxoplasmosis.
-
Prospective randomized trial of trimethoprim/sulfamethoxazole versus Pyrimethamine and Sulfadiazine in the treatment of ocular toxoplasmosis.
Ophthalmology, 2005Co-Authors: Masoud Soheilian, Mohammad Mehdi Sadoughi, Mehdi Ghajarnia, Mohammad H Dehghan, Shahin Yazdani, Hassan Behboudi, Arash Anisian, Gholam A PeymanAbstract:Objective To compare the efficacy of the classic treatment of ocular toxoplasmosis (Pyrimethamine, Sulfadiazine, and prednisolone) with a regimen consisting of trimethoprim/sulfamethoxazole (co-trimoxazole) plus prednisolone. Design Prospective randomized single-blind clinical trial. Participants Fifty-nine patients with active ocular toxoplasmosis were randomly assigned to 2 treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine, and 30 patients received trimethoprim/sulfamethoxazole. Intervention Treatment consisted of 6 weeks' treatment with antibiotics plus steroids. Antitoxoplasmosis antibodies (immunoglobulin M [IgM] and IgG) were measured using an enzyme-linked immunosorbent assay. Main Outcome Measures Changes in retinochoroidal lesion size after 6 weeks' treatment, visual acuity (VA) before and after intervention, adverse drug reactions during follow-up, and rate of recurrence. Results Active toxoplasmosis retinochoroiditis resolved in all patients over 6 weeks' treatment, with no significant difference in mean reduction of retinochoroidal lesion size between the 2 treatment groups (61% reduction in the classic treatment group and 59% in the trimethoprim/sulfamethoxazole group, P = 0.75). Similarly, no significant difference was found in VA after treatment between the 2 groups (mean VAs after treatment were 0.12 logarithm of the minimum angle of resolution [logMAR] [20/25] in the classic treatment group and 0.09 logMAR [20/25] in the trimethoprim/sulfamethoxazole group, P = 0.56). Adverse effects were similar in both groups, with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 24 months' follow-up was 10.16%, with no significant difference between the treatment groups ( P = 0.64). Conclusions Drug efficacies in terms of reduction in retinal lesion size and improvement in VA were similar in a regimen of trimethoprim/sulfamethoxazole and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with trimethoprim/sulfamethoxazole seems to be an acceptable alternative for the treatment of ocular toxoplasmosis.
Arash Anisian - One of the best experts on this subject based on the ideXlab platform.
-
Short-term Results of Two Treatment Regimens in Ocular Toxoplasmosis: Trimethoprim/Sulfamethoxazole versus Pyrimethamine and Sulfadiazine
Journal of ophthalmic and vision research, 2006Co-Authors: Mohammad Mehdi Sadoughi, Mohammad H Dehghan, Hassan Behboudi, Arash Anisian, Soheylian Masoud, Yazdani ShahinAbstract:Purpose : To compare the efficacy of classic treatment for ocular toxoplasmosis (Pyrimethamine, Sulfadiazine and predinsolone) with a regimen consisting of trimethoprim/sulfamethoxazole (TMP/SMX) [co-trimoxazole] plus predinsolone. Methods : In a prospective randomized single-blind clinical trial, 59 patients with active ocular toxoplasmosis were randomly assigned to two treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine and 30 patients received TMP/SMX. Treatment consisted of six weeks treatment with antibiotics plus steroids. Anti-toxoplasmosis antibodies (IgM and IgG) were measured using ELISA. Outcome measures included changes in retinochoroidal lesion size after six weeks of treatment, visual acuity before and after intervention, adverse drug reactions during follow up and rate of recurrence. Results : Active toxoplasmosis retinochoroiditis resolved in all patients over six weeks of treatment with no significant difference in mean reduction in retinochoroidal lesion size between the two treatment groups (61% reduction in the classic treatment group and 59% in the TMP/SMX group, P=0.75). Similarly no significant difference was found in visual acuity after treatment between the two groups [mean visual acuity after treatment was 0.12 LogMAR (20/25) in classic treatment group and 0.09LogMAR (20/25) in TMP/SMX group, P = 0.56]. Adverse events were similar in both groups with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 14 months of follow up was 6.7% with no significant difference between the treatment groups (P = 0.48). Conclusion : Drug efficacy in terms of reduction in retinal lesion size and improvement in visual acuity was similar between a regimen of TMP/SMX and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with TMP/SMX appears to be an acceptable alternative for the treatment of ocular toxoplasmosis.
-
short term results of two treatment regimens in ocular toxoplasmosis trimethoprim sulfamethoxazole versus Pyrimethamine and Sulfadiazine
Journal of ophthalmic and vision research, 2006Co-Authors: Mohammad Mehdi Sadoughi, Mohammad H Dehghan, Hassan Behboudi, Arash Anisian, Soheylian Masoud, Yazdani ShahinAbstract:Purpose : To compare the efficacy of classic treatment for ocular toxoplasmosis (Pyrimethamine, Sulfadiazine and predinsolone) with a regimen consisting of trimethoprim/sulfamethoxazole (TMP/SMX) [co-trimoxazole] plus predinsolone. Methods : In a prospective randomized single-blind clinical trial, 59 patients with active ocular toxoplasmosis were randomly assigned to two treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine and 30 patients received TMP/SMX. Treatment consisted of six weeks treatment with antibiotics plus steroids. Anti-toxoplasmosis antibodies (IgM and IgG) were measured using ELISA. Outcome measures included changes in retinochoroidal lesion size after six weeks of treatment, visual acuity before and after intervention, adverse drug reactions during follow up and rate of recurrence. Results : Active toxoplasmosis retinochoroiditis resolved in all patients over six weeks of treatment with no significant difference in mean reduction in retinochoroidal lesion size between the two treatment groups (61% reduction in the classic treatment group and 59% in the TMP/SMX group, P=0.75). Similarly no significant difference was found in visual acuity after treatment between the two groups [mean visual acuity after treatment was 0.12 LogMAR (20/25) in classic treatment group and 0.09LogMAR (20/25) in TMP/SMX group, P = 0.56]. Adverse events were similar in both groups with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 14 months of follow up was 6.7% with no significant difference between the treatment groups (P = 0.48). Conclusion : Drug efficacy in terms of reduction in retinal lesion size and improvement in visual acuity was similar between a regimen of TMP/SMX and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with TMP/SMX appears to be an acceptable alternative for the treatment of ocular toxoplasmosis.
-
prospective randomized trial of trimethoprim sulfamethoxazole versus Pyrimethamine and Sulfadiazine in the treatment of ocular toxoplasmosis
Ophthalmology, 2005Co-Authors: Masoud Soheilian, Mohammad Mehdi Sadoughi, Mehdi Ghajarnia, Mohammad H Dehghan, Shahin Yazdani, Hassan Behboudi, Arash Anisian, Gholam A PeymanAbstract:Objective To compare the efficacy of the classic treatment of ocular toxoplasmosis (Pyrimethamine, Sulfadiazine, and prednisolone) with a regimen consisting of trimethoprim/sulfamethoxazole (co-trimoxazole) plus prednisolone. Design Prospective randomized single-blind clinical trial. Participants Fifty-nine patients with active ocular toxoplasmosis were randomly assigned to 2 treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine, and 30 patients received trimethoprim/sulfamethoxazole. Intervention Treatment consisted of 6 weeks' treatment with antibiotics plus steroids. Antitoxoplasmosis antibodies (immunoglobulin M [IgM] and IgG) were measured using an enzyme-linked immunosorbent assay. Main Outcome Measures Changes in retinochoroidal lesion size after 6 weeks' treatment, visual acuity (VA) before and after intervention, adverse drug reactions during follow-up, and rate of recurrence. Results Active toxoplasmosis retinochoroiditis resolved in all patients over 6 weeks' treatment, with no significant difference in mean reduction of retinochoroidal lesion size between the 2 treatment groups (61% reduction in the classic treatment group and 59% in the trimethoprim/sulfamethoxazole group, P = 0.75). Similarly, no significant difference was found in VA after treatment between the 2 groups (mean VAs after treatment were 0.12 logarithm of the minimum angle of resolution [logMAR] [20/25] in the classic treatment group and 0.09 logMAR [20/25] in the trimethoprim/sulfamethoxazole group, P = 0.56). Adverse effects were similar in both groups, with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 24 months' follow-up was 10.16%, with no significant difference between the treatment groups ( P = 0.64). Conclusions Drug efficacies in terms of reduction in retinal lesion size and improvement in VA were similar in a regimen of trimethoprim/sulfamethoxazole and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with trimethoprim/sulfamethoxazole seems to be an acceptable alternative for the treatment of ocular toxoplasmosis.
-
Prospective randomized trial of trimethoprim/sulfamethoxazole versus Pyrimethamine and Sulfadiazine in the treatment of ocular toxoplasmosis.
Ophthalmology, 2005Co-Authors: Masoud Soheilian, Mohammad Mehdi Sadoughi, Mehdi Ghajarnia, Mohammad H Dehghan, Shahin Yazdani, Hassan Behboudi, Arash Anisian, Gholam A PeymanAbstract:Objective To compare the efficacy of the classic treatment of ocular toxoplasmosis (Pyrimethamine, Sulfadiazine, and prednisolone) with a regimen consisting of trimethoprim/sulfamethoxazole (co-trimoxazole) plus prednisolone. Design Prospective randomized single-blind clinical trial. Participants Fifty-nine patients with active ocular toxoplasmosis were randomly assigned to 2 treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine, and 30 patients received trimethoprim/sulfamethoxazole. Intervention Treatment consisted of 6 weeks' treatment with antibiotics plus steroids. Antitoxoplasmosis antibodies (immunoglobulin M [IgM] and IgG) were measured using an enzyme-linked immunosorbent assay. Main Outcome Measures Changes in retinochoroidal lesion size after 6 weeks' treatment, visual acuity (VA) before and after intervention, adverse drug reactions during follow-up, and rate of recurrence. Results Active toxoplasmosis retinochoroiditis resolved in all patients over 6 weeks' treatment, with no significant difference in mean reduction of retinochoroidal lesion size between the 2 treatment groups (61% reduction in the classic treatment group and 59% in the trimethoprim/sulfamethoxazole group, P = 0.75). Similarly, no significant difference was found in VA after treatment between the 2 groups (mean VAs after treatment were 0.12 logarithm of the minimum angle of resolution [logMAR] [20/25] in the classic treatment group and 0.09 logMAR [20/25] in the trimethoprim/sulfamethoxazole group, P = 0.56). Adverse effects were similar in both groups, with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 24 months' follow-up was 10.16%, with no significant difference between the treatment groups ( P = 0.64). Conclusions Drug efficacies in terms of reduction in retinal lesion size and improvement in VA were similar in a regimen of trimethoprim/sulfamethoxazole and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with trimethoprim/sulfamethoxazole seems to be an acceptable alternative for the treatment of ocular toxoplasmosis.
Hassan Behboudi - One of the best experts on this subject based on the ideXlab platform.
-
Short-term Results of Two Treatment Regimens in Ocular Toxoplasmosis: Trimethoprim/Sulfamethoxazole versus Pyrimethamine and Sulfadiazine
Journal of ophthalmic and vision research, 2006Co-Authors: Mohammad Mehdi Sadoughi, Mohammad H Dehghan, Hassan Behboudi, Arash Anisian, Soheylian Masoud, Yazdani ShahinAbstract:Purpose : To compare the efficacy of classic treatment for ocular toxoplasmosis (Pyrimethamine, Sulfadiazine and predinsolone) with a regimen consisting of trimethoprim/sulfamethoxazole (TMP/SMX) [co-trimoxazole] plus predinsolone. Methods : In a prospective randomized single-blind clinical trial, 59 patients with active ocular toxoplasmosis were randomly assigned to two treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine and 30 patients received TMP/SMX. Treatment consisted of six weeks treatment with antibiotics plus steroids. Anti-toxoplasmosis antibodies (IgM and IgG) were measured using ELISA. Outcome measures included changes in retinochoroidal lesion size after six weeks of treatment, visual acuity before and after intervention, adverse drug reactions during follow up and rate of recurrence. Results : Active toxoplasmosis retinochoroiditis resolved in all patients over six weeks of treatment with no significant difference in mean reduction in retinochoroidal lesion size between the two treatment groups (61% reduction in the classic treatment group and 59% in the TMP/SMX group, P=0.75). Similarly no significant difference was found in visual acuity after treatment between the two groups [mean visual acuity after treatment was 0.12 LogMAR (20/25) in classic treatment group and 0.09LogMAR (20/25) in TMP/SMX group, P = 0.56]. Adverse events were similar in both groups with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 14 months of follow up was 6.7% with no significant difference between the treatment groups (P = 0.48). Conclusion : Drug efficacy in terms of reduction in retinal lesion size and improvement in visual acuity was similar between a regimen of TMP/SMX and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with TMP/SMX appears to be an acceptable alternative for the treatment of ocular toxoplasmosis.
-
short term results of two treatment regimens in ocular toxoplasmosis trimethoprim sulfamethoxazole versus Pyrimethamine and Sulfadiazine
Journal of ophthalmic and vision research, 2006Co-Authors: Mohammad Mehdi Sadoughi, Mohammad H Dehghan, Hassan Behboudi, Arash Anisian, Soheylian Masoud, Yazdani ShahinAbstract:Purpose : To compare the efficacy of classic treatment for ocular toxoplasmosis (Pyrimethamine, Sulfadiazine and predinsolone) with a regimen consisting of trimethoprim/sulfamethoxazole (TMP/SMX) [co-trimoxazole] plus predinsolone. Methods : In a prospective randomized single-blind clinical trial, 59 patients with active ocular toxoplasmosis were randomly assigned to two treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine and 30 patients received TMP/SMX. Treatment consisted of six weeks treatment with antibiotics plus steroids. Anti-toxoplasmosis antibodies (IgM and IgG) were measured using ELISA. Outcome measures included changes in retinochoroidal lesion size after six weeks of treatment, visual acuity before and after intervention, adverse drug reactions during follow up and rate of recurrence. Results : Active toxoplasmosis retinochoroiditis resolved in all patients over six weeks of treatment with no significant difference in mean reduction in retinochoroidal lesion size between the two treatment groups (61% reduction in the classic treatment group and 59% in the TMP/SMX group, P=0.75). Similarly no significant difference was found in visual acuity after treatment between the two groups [mean visual acuity after treatment was 0.12 LogMAR (20/25) in classic treatment group and 0.09LogMAR (20/25) in TMP/SMX group, P = 0.56]. Adverse events were similar in both groups with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 14 months of follow up was 6.7% with no significant difference between the treatment groups (P = 0.48). Conclusion : Drug efficacy in terms of reduction in retinal lesion size and improvement in visual acuity was similar between a regimen of TMP/SMX and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with TMP/SMX appears to be an acceptable alternative for the treatment of ocular toxoplasmosis.
-
prospective randomized trial of trimethoprim sulfamethoxazole versus Pyrimethamine and Sulfadiazine in the treatment of ocular toxoplasmosis
Ophthalmology, 2005Co-Authors: Masoud Soheilian, Mohammad Mehdi Sadoughi, Mehdi Ghajarnia, Mohammad H Dehghan, Shahin Yazdani, Hassan Behboudi, Arash Anisian, Gholam A PeymanAbstract:Objective To compare the efficacy of the classic treatment of ocular toxoplasmosis (Pyrimethamine, Sulfadiazine, and prednisolone) with a regimen consisting of trimethoprim/sulfamethoxazole (co-trimoxazole) plus prednisolone. Design Prospective randomized single-blind clinical trial. Participants Fifty-nine patients with active ocular toxoplasmosis were randomly assigned to 2 treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine, and 30 patients received trimethoprim/sulfamethoxazole. Intervention Treatment consisted of 6 weeks' treatment with antibiotics plus steroids. Antitoxoplasmosis antibodies (immunoglobulin M [IgM] and IgG) were measured using an enzyme-linked immunosorbent assay. Main Outcome Measures Changes in retinochoroidal lesion size after 6 weeks' treatment, visual acuity (VA) before and after intervention, adverse drug reactions during follow-up, and rate of recurrence. Results Active toxoplasmosis retinochoroiditis resolved in all patients over 6 weeks' treatment, with no significant difference in mean reduction of retinochoroidal lesion size between the 2 treatment groups (61% reduction in the classic treatment group and 59% in the trimethoprim/sulfamethoxazole group, P = 0.75). Similarly, no significant difference was found in VA after treatment between the 2 groups (mean VAs after treatment were 0.12 logarithm of the minimum angle of resolution [logMAR] [20/25] in the classic treatment group and 0.09 logMAR [20/25] in the trimethoprim/sulfamethoxazole group, P = 0.56). Adverse effects were similar in both groups, with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 24 months' follow-up was 10.16%, with no significant difference between the treatment groups ( P = 0.64). Conclusions Drug efficacies in terms of reduction in retinal lesion size and improvement in VA were similar in a regimen of trimethoprim/sulfamethoxazole and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with trimethoprim/sulfamethoxazole seems to be an acceptable alternative for the treatment of ocular toxoplasmosis.
-
Prospective randomized trial of trimethoprim/sulfamethoxazole versus Pyrimethamine and Sulfadiazine in the treatment of ocular toxoplasmosis.
Ophthalmology, 2005Co-Authors: Masoud Soheilian, Mohammad Mehdi Sadoughi, Mehdi Ghajarnia, Mohammad H Dehghan, Shahin Yazdani, Hassan Behboudi, Arash Anisian, Gholam A PeymanAbstract:Objective To compare the efficacy of the classic treatment of ocular toxoplasmosis (Pyrimethamine, Sulfadiazine, and prednisolone) with a regimen consisting of trimethoprim/sulfamethoxazole (co-trimoxazole) plus prednisolone. Design Prospective randomized single-blind clinical trial. Participants Fifty-nine patients with active ocular toxoplasmosis were randomly assigned to 2 treatment groups: 29 were treated with Pyrimethamine/Sulfadiazine, and 30 patients received trimethoprim/sulfamethoxazole. Intervention Treatment consisted of 6 weeks' treatment with antibiotics plus steroids. Antitoxoplasmosis antibodies (immunoglobulin M [IgM] and IgG) were measured using an enzyme-linked immunosorbent assay. Main Outcome Measures Changes in retinochoroidal lesion size after 6 weeks' treatment, visual acuity (VA) before and after intervention, adverse drug reactions during follow-up, and rate of recurrence. Results Active toxoplasmosis retinochoroiditis resolved in all patients over 6 weeks' treatment, with no significant difference in mean reduction of retinochoroidal lesion size between the 2 treatment groups (61% reduction in the classic treatment group and 59% in the trimethoprim/sulfamethoxazole group, P = 0.75). Similarly, no significant difference was found in VA after treatment between the 2 groups (mean VAs after treatment were 0.12 logarithm of the minimum angle of resolution [logMAR] [20/25] in the classic treatment group and 0.09 logMAR [20/25] in the trimethoprim/sulfamethoxazole group, P = 0.56). Adverse effects were similar in both groups, with one patient in each suffering from any significant drug side effects. The overall recurrence rate after 24 months' follow-up was 10.16%, with no significant difference between the treatment groups ( P = 0.64). Conclusions Drug efficacies in terms of reduction in retinal lesion size and improvement in VA were similar in a regimen of trimethoprim/sulfamethoxazole and the classic treatment of ocular toxoplasmosis with Pyrimethamine and Sulfadiazine. Therapy with trimethoprim/sulfamethoxazole seems to be an acceptable alternative for the treatment of ocular toxoplasmosis.
